메뉴 건너뛰기




Volumn 5, Issue 4, 2016, Pages

Vemurafenib and ipilimumab: A promising combination? Results of a case series

Author keywords

BRAF inhibitors; immune checkpoint blocker; ; ipilimumab; melanoma; targeted treatment; vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; IPILIMUMAB; LACTATE DEHYDROGENASE; VEMURAFENIB;

EID: 84962809846     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1101207     Document Type: Article
Times cited : (17)

References (14)
  • 2
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma. A multicenter, open-label, phase 3 randomised controlled trial
    • 22735384
    • A.Hauschild, J.J.Grob, L.V.Demidov, T.Jouary, R.Gutzmer, M.Millward, P.Rutkowski, C.U.Blank, W.H.MillerJr, E.Kaempgen et al. Dabrafenib in BRAF-mutated metastatic melanoma. A multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3    Jouary, T.4    Gutzmer, R.5    Millward, M.6    Rutkowski, P.7    Blank, C.U.8    Miller, W.H.9    Kaempgen, E.10
  • 4
    • 84945487247 scopus 로고    scopus 로고
    • Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors
    • 26218930
    • A.M.Menzies, J.S.Wilmott, M.Drummond, S.Lo, M.Lyle, M.M.Chan, J.F.Thompson, A.Guminski, M.S.Carlino, R.A.Scolyer et al. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 2015; 121:3826-35; PMID:26218930; http://dx.doi.org/10.1002/cncr.29586
    • (2015) Cancer
    • Menzies, A.M.1    Wilmott, J.S.2    Drummond, M.3    Lo, S.4    Lyle, M.5    Chan, M.M.6    Thompson, J.F.7    Guminski, A.8    Carlino, M.S.9    Scolyer, R.A.10
  • 5
    • 84928917822 scopus 로고    scopus 로고
    • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
    • 25667295
    • D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
    • (2015) J Clin Oncol , vol.33 , pp. 1889-1894
    • Schadendorf, D.1    Hodi, F.S.2    Robert, C.3    Weber, J.S.4    Margolin, K.5    Hamid, O.6    Patt, D.7    Chen, T.T.8    Berman, D.M.9    Wolchok, J.D.10
  • 7
    • 84875785905 scopus 로고    scopus 로고
    • Hepatotoxicity with combination of vemurafenib and ipilimumab
    • 23550685
    • A.Ribas, F.S.Hodi, M.Callahan, C.Konto, J.Wolchok. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc-1302338
    • (2013) N Engl J Med , vol.368 , pp. 1365-1366
    • Ribas, A.1    Hodi, F.S.2    Callahan, M.3    Konto, C.4    Wolchok, J.5
  • 10
    • 84874872137 scopus 로고    scopus 로고
    • BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma
    • 23307859
    • D.Frederick, A.Piris, A.P.Cogdill, Z.A.Cooper, C.Lezcano, C.R.Ferrone, D.Mitra, A.Boni, L.P.Newton, C.Liu et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630
    • (2013) Clin Cancer Res , vol.19 , pp. 1225-1231
    • Frederick, D.1    Piris, A.2    Cogdill, A.P.3    Cooper, Z.A.4    Lezcano, C.5    Ferrone, C.R.6    Mitra, D.7    Boni, A.8    Newton, L.P.9    Liu, C.10
  • 12
    • 84939258997 scopus 로고    scopus 로고
    • Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
    • 25996827
    • D.R.Minor, I.Puzanov, M.K.Callahan, B.A.Hug, A.Hoos. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res 2015; 28:611-2; PMID:25996827; http://dx.doi.org/10.1111/pcmr.12383
    • (2015) Pigment Cell Melanoma Res , vol.28 , pp. 611-612
    • Minor, D.R.1    Puzanov, I.2    Callahan, M.K.3    Hug, B.A.4    Hoos, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.